Soluble CD14 antigen

Details Soluble CD14 antigen Soluble CD14 antigen

2005-05-11

2009-10-27

Haddad, Maher M (Department: 1644)

Chemistry: natural resins or derivatives; peptides or proteins;

Peptides of 3 to 100 amino acid residues

C530S324000, C530S333000, C530S344000

Reexamination Certificate

active

07608684

ABSTRACT:
There are provided a soluble CD14 antigen which is a novel in vivo protein useful as a marker for diagnosing sepsis and has the following characteristic features 1) to 3):1) a molecular weight of 13±2 kDa when measured by SDS-PAGE under non-reducing conditions;2) an amino acid sequence in which the amino acid sequence of SEQ ID NO:1 is present on its N terminal; and3) ability to specifically bind to an antibody prepared by using a peptide comprising 16 amino acid residues described in SEQ ID NO:2 for the antigen; and a recombinant soluble CD14 fragment.

REFERENCES:
patent: 5766593 (1998-06-01), Lichenstein et al.
patent: 6916628 (2005-07-01), Furusako et al.
patent: 2004/0141917 (2004-07-01), Achen et al.
patent: 286 876 (1983-10-01), None
patent: 1 213 586 (2002-06-01), None
patent: 1 275 713 (2003-01-01), None
patent: 1336620 (2003-08-01), None
patent: 2005-106694 (2005-04-01), None
patent: WO-96/20956 (1996-07-01), None
patent: WO01/22085 (2001-03-01), None
patent: WO-01/22085 (2001-03-01), None
patent: WO-01/72993 (2001-10-01), None
patent: WO-02/42333 (2002-05-01), None
Coleman et al. Research in Immunology, 1994; 145(1): 33-36.
Abaza et al. Journal of Protein Chemistry, vol. 11, No. 5, 1992, pp. 433-444.
Lederman et al. 1991. Molecular Immunology 28: 1171-1181.
Li et al. PNAS. 1980. 77: 3211-3214.
Kim et al. JBC 2005, 208:11347-11351. A copy is not provided herein.
Haziot et al. The Journal of Immunology 1988. 141:547-552.
Landmann, Regine et al.; The Journal of Infectious Disease; vol. 171, pp. 639-644 (1995).
Stelter, Felix et al.; European Journal of Biochemistry, vol. 236, pp. 457-464 (1996).
Juan, Todd S.-C. et al.; The Journal of Biological Chemistry; vol. 270, No. 3, pp. 1382-1387 (1995).
Majerle, Andreja et al., European Journal of Physiology; vol. 439 [Suppl.], pp. R109-R110 (2000).
Bazil, Vladimir et al.; European Journal of Immunology, vol. 16, pp. 1583-1589 (1986).
Schütt, Christine et al., Allerg. Immunol., vol. 34, pp. 17-26 (1988) (Summary at p. 17 in English).
van Voorhis, Wesley C. et al., Journal of Experimental Medicine; vol. 158, pp. 126-145 (1983).
Bazil, Vladimir et al., Molecular Immunology, vol. 26, No. 7, pp. 657-662 (1989).
Grunwald, U. et al., Journal of Immunological Methods, vol. 155, pp. 225-232 (1992).
Burgmann, Heinz et al., Clinical Immunology and Immunopathology, vol. 80, No. 8, pp. 307-310 (1996).
Endo et al., The Japanese Association fo Infectious Diseases, the 52nd East Japan Meeting held on Oct. 31, 2003 Abstract No. 123 (with English translation).
Endo et al., Journal of Japanese Association for Acute Medicine, vol. 14, No. 10, p. 602 (Oct. 2003) (with English translation).
The Official Journal of The Shock Society, Abstract of the 6th World Congress on Trauma, Shock, Inflammation and Sepsis (Mar. 2004).
Endo et al., Journal of the Japanese Society of Intensive Care Medicine, vol. 11 Supplement, p. 244 (Jan. 2004) (with English translation).
The Official Journal of the Critical Care Forum, vol. 8, Supplement 1, pp. S94-S95 (Mar. 2004).
Abstract in the 104th General Assembly of the Japan Surgical Society (Apr. 2004); (with English translation).
Official Journal of The European Society of Intensive Care Medicine and The European Society of Paediatric & Neonatal Intensive Care, Vol. 30, Supplement 1, p. S192 (Sep. 2004).
Endo et al., Program and Abstracts of the 10th Conference of the Japan Endotoxin Society, Nov. 15, 2004 (with English translation).
Journal of Endotoxin Research, vol. 10, No. 5, p. 373 (Nov. 2004).
Endo et al., Journal of The Japanese Society of Intensive Care Medicine, vol. 12 Supplement, p. 121 (Jan. 2005) (with English translation).
Endo et al., The Journal of the Japanese Association of Infectious Diseases, vol. 80 Supplement, p. 271, (Mar. 2006) (with English translation).
Endo et al., Japan Journal of Critical Care for Endotoxemia, vol. 9, No. 1, pp. 46-50 (2005) (English Abstract is on p. 50).
Yaegashi et al., J .Infect. Chemother. , vol. 11, pp. 234-238 ( Mar. 2005).
Manocha, Sanjay et al.; Expert Opinion Investig. Drugs; vol. 11, No. 12, pp. 1795-1812 (2002).
Manocha, Sanjay et al.; Expert Opinion Investig. Drugs; vol. 11, No. 12, pp. 1795-1812 (2002).
Yaegashi et al., “Evaluation of a newly identified soluble CD14 subtype as a marker for sepsis,” J Infect Chemother (2005), vol. 11 , pp. 234-238.
Bufler et al., “Soluble lipopolysaccharide receptor (CD14) is released via two different mechanisms from human monocytes and CD14 transfectants,” Eur. J. Immunol, 1995, vol. 25, pp. 604-610.
Majerle et al., “Bacterial expression and refolding of different fragments of human CD14,” Pflugers Arch: Eur J Physiol (2000) vol. 439 (Suppl); R109-R110.
Majerle et al., “Expression and Refolding of Functional Fragments of the Human Lipopolysaccharide Receptor CD14 inEscherichia coliandPichia pastoris.” Protein Expression and Purification, vol. 17, pp. 96-104 (1999).
Stelter et al., “Mutation of amino acids 39-44 of human CD14 abrogates binding of lipopolysaccharide andEscherichia coli,” Eur. J. Biochem., vol. 243, pp. 100-109 (1997).
Iwaki et al., “The CD14 region spanning amino acids 57-64 is critical for interaction with the extracellular Toll-like receptor 2 domain,” Biochemical and Biophysical Research Communications, vol. 328 (2005). pp. 173-176.
D. Levenson, Clinical Laboratory News Jan. 2008, vol. 34, No. 1, [retrieved on Feb. 12, 2008]. Retrieved from the Internet: URL: http://www.aacc.org/AACC/publications/cln/2008/jan/cover1—0108.htm, p. 1-8.
C. Wenisch et al., “Elevated levels of soluble CD14 in serum of patients with acute Plasmodium falciparum malaria,” Clin. Exp. Immunol. 1996; vol. 105, pp. 74-78.
E. Lien et al., “Elevated Levels of Serum-Soluble CD14 in Human Immunodeficiency Virus Type 1 (HIV-1) Infection: Correlation to Disease Progression and Clinical Events,” Blood, vol. 92, No. 6, pp. 2084-2092, Sep. 1998.

Affiliated with

Also associated with

Rating

Soluble CD14 antigen does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Soluble CD14 antigen, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Soluble CD14 antigen will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4059899